Storia in 5 fonti

Capricor Duchenne cell therapy voted down by FDA panel

At a contentious meeting with possible implications for other rare disease drugmakers, outside experts ultimately determined that Capricor didn't prove deramiocel's benefits in Duchenne-related cardiomyopathy.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 g fa

Capricor Duchenne cell therapy voted down by FDA panel

originale

Timeline cronologica

lunedì 27 luglio 2026·statnews.com
Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.
lunedì 27 luglio 2026·medpagetoday.com
FDA Scientists Raise Questions About Duchenne Drug
Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data

Capricor Duchenne cell therapy voted down by FDA panel

Confronto fonti

Capricor Duchenne cell therapy voted down by FDA panel

Timeline cronologica

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

FDA Scientists Raise Questions About Duchenne Drug

Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

FDA Committee Votes Down Duchenne Drug

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Capricor shares plunge after FDA says DMD therapy lacks efficacy ahead of adcomm

Capricor Duchenne cell therapy voted down by FDA panel

FDA expert panel recommends against approval of Capricor’s Duchenne drug

FDA expert committee reviews Capricor Therapeutics’ Duchenne drug

FDA Committee Votes Down Duchenne Drug

FDA and Capricor clash over deramiocel efficacy data at Duchenne adcomm vote